Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP ...

FDA-approved oral GLP-1s match injectables in weight loss effectiveness with similar side effects and health benefits. There are differences, however.

The new 12-month project extends a prior two-year award for which Habegger studied mechanisms of glucagon, Glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) and ...

The paper, titled, "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study," was published in Obesity, the peer-reviewed ...

Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

By Tarun Sai Lomte From laboratory models to small human trials, a new review explores whether popular metabolic drugs could help curb alcohol, nicotine, and drug use, while underscoring how much ...

As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of obesity. They foresee a future of personalized obesity medicine similar to the ...

In this study, researchers matched patients using GLP-1RA therapy to those using aspirin to compare colorectal cancer incidence in each population.

Did you know that weight-loss drugs might have the potential to heal the habit of substance abuse?In a recent study published ...

The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to hit the market and disrupt the medical sector. These treatments are ...

A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p 54% of participants on the 24 mg dose achieved resolution of obesity (BMI C ...